DT15 Rec'd PCT/PTO 2 3 FEB 2005

#### **PATENT**

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): Kevin Jon Williams

U.S. National Stage of PCT/US03/26023 International Filing Date: August 20, 2003

Filed: February 23, 2005 Examiner:

Att. Docket No.: W1107/20010 Confirmation No.:

For: THROMBOSPONDIN FRAGMENTS AND USES THEREOF IN CLINICAL

ASSAYS FOR CANCER AND GENERATION OF ANTIBODIES AND OTHER

**BINDING AGENTS** 

### PRELIMINARY AMENDMENT

Mail Stop PCT Attention DO/EO/US Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## **INTRODUCTORY COMMENTS**

Prior to initial examination on the merits, please amend the above-identified application as follows:

#### AMENDMENTS TO THE SPECIFICATION

Please add the following to the specification after page 50, line 6:

- --The current inventions may be further summarized and numbered in the following fashion (using 164 numbered Paragraphs) analogous to the procedure for numbering claims, where the word "Paragraph has been substituted for the word "Claim":
- 1. A purified thrombospondin fragment that has been extracted from a bodily fluid, said fragment being one within a molecular weight range selected from the group consisting of 80 to 110 kDA, 40 to 60 kDa, and 20 to 35 kDa, wherein the size in kDa is that determined by gel electrophoresis after disulfide bond reduction.